Furthermore, European populations harbour the highest frequencies of CFTR trafficking mutations, suggesting that the rate of cystic fibrosis patients responding to CFTR correctors is overall higher in Europe compared to other populations. The gene discussed is CFTR; the disease is cystic fibrosis.